Buyukberber S, Sari I, Camci C, Buyukberber N M, Sevinc A, Turk H M
Department of Medical Oncology, Gazi University, Medical Faculty, Gazi Hospital, Ankara, 06500.
Med Oncol. 2007;24(2):245-9. doi: 10.1007/BF02698047.
It is suggested that adrenomedullin (AM) plays a role in lung carcinogenesis although, to confirm this suggestion, further clinical studies are needed to determine its relationship with prognosis in lung cancer. Archived 50 paraffin-embedded tumor samples of the lung were retrospectively evaluated for AM expression by immunohistochemistry and analyzed for a possible correlation with patient characteristics and survival. Quantitation of immunoreactivity was accomplished using an immunohistochemical scoring system. The pulmonary resection specimens contained 22 squamous cell carcinomas, 15 adenocarcinomas, and 13 small cell carcinomas. Non-small cell carcinomas of the lung were more likely to express AM than small cell carcinomas of the lung. Ninety-one percent of squamous cell carcinomas and 87% of adenocarcinomas expressed AM at a moderate to strong level and grade2-4 (30-100%), which were significantly higher from the non-neo-plastic lung tissue. Twenty-three percent of small cell carcinomas of lung expressed AM. Interestingly, AM immunoreactivity was essentially weak and grade 1 (<%30) in this group. AM expression is upregulated in non-small cell carcinomas of the lung, whereas it is downregulated in small cell carcinomas and non-neo-plastic lung tissues. AM expression did not show any correlation with the differentiation of the tumor, the stage of cancer, and the overall survival of patients. These results did not support the role of adrenomedullin as an independent survival factor for lung cancer. However, AM inhibition in conjunction with other anti-angiogenic agents may be useful in the prevention and treatment of malignancies.
有研究表明，肾上腺髓质素（AM）在肺癌发生过程中发挥作用，不过，为证实这一观点，还需要进一步的临床研究来确定其与肺癌预后的关系。对存档的50份肺石蜡包埋肿瘤样本进行回顾性评估，采用免疫组织化学法检测AM表达，并分析其与患者特征及生存情况的可能相关性。使用免疫组织化学评分系统对免疫反应性进行定量分析。肺切除标本包含22例鳞状细胞癌、15例腺癌和13例小细胞癌。肺非小细胞癌比肺小细胞癌更易表达AM。91%的鳞状细胞癌和87%的腺癌以中度至强水平及2-4级（30%-100%）表达AM，显著高于非肿瘤性肺组织。23%的肺小细胞癌表达AM。有趣的是，该组中AM免疫反应性基本较弱且为1级（<30%）。AM在肺非小细胞癌中表达上调，而在小细胞癌和非肿瘤性肺组织中表达下调。AM表达与肿瘤分化、癌症分期及患者总生存期均无相关性。这些结果不支持肾上腺髓质素作为肺癌独立生存因子的作用。然而，AM抑制与其他抗血管生成药物联合使用可能对恶性肿瘤的预防和治疗有用。
